US20080045605A1 - Image Quality in the Eye - Google Patents
Image Quality in the Eye Download PDFInfo
- Publication number
- US20080045605A1 US20080045605A1 US11/629,997 US62999705A US2008045605A1 US 20080045605 A1 US20080045605 A1 US 20080045605A1 US 62999705 A US62999705 A US 62999705A US 2008045605 A1 US2008045605 A1 US 2008045605A1
- Authority
- US
- United States
- Prior art keywords
- zeaxanthin
- lutein
- mixtures
- image quality
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Definitions
- image quality refers to the image formed on the retina. This image can be deteriorated by higher-order aberrations such as spherical aberrations, coma and irregular astigmatism.
- Higher-order aberrations are aberrations of the optics of the eye above and beyond nearsightedness, farsightedness and astigmatism. Higher-order aberrations cannot be corrected easily with glasses or contact lenses. Higher-order wavefront aberrations describe small deviations of the wavefront surface from the ideal surface and the reproduction of these deviations require a large number of components. Two common and potentially disruptive higher order aberrations are “spherical aberration” and “coma” see Liang J, Williams D R; Aberrations and retinal image quality of the normal human eye; J. Opt. Soc. Am. A. 1997; 14 (11):2873-83).
- the invention relates to the use of lutein or zeaxanthin, or mixtures thereof, in the manufacture of a composition for reducing higher-order wavefront aberrations in the human eye.
- the present invention relates to a method of reducing higher-order wavefront aberrations in the human eye which comprises administering to a person in need of such treatment an effective amount of lutein or zeaxanthin, or mixtures thereof.
- higher order wavefront aberrations in the eye denotes aberrations of the optical system of the eye that are distinct from myopia, hyperopia and axial astigmatism but nevertheless influence the quality of the image formed on the retina. They are measured by commercially available apparatuses, and are expressed as the wavefront function, which completely describes the aggregate effects of all refractive parts of the eye on light passing through every location of the pupil.
- the wavefront aberration function is a way of quantifying the imperfections of the optics of the eye that cause degradation of retinal image quality.
- the “ideal” wavefront is generated when a “point” on the retina is imaged through the optics of the eye as a plane and flat surface just outside the eye. This means that all the rays emerging from the eye form a parallel bundle and are perpendicular to this plane.
- the “real” wavefront surface is not a perfect two-dimensional plane and reflects the aberrations present in the optical system. It is usually represented mathematically by a series of terms known as Zernike polynomials. A knowledge of the coefficients of the Zernike polynomials provides a complete description of the wavefront surface.
- the root mean square (rms) deviation is calculated by computing the root of the mean of the squares of the actual deviations from the ideal plane.
- the rms value is equivalent to a standard deviation, but the two functions compared are 2D surfaces (i.e., the ideal wavefront and the actual wavefront).
- the wavefront aberrations are measured with a wavefront analyzer (see, e.g., J. Refract. Surg. 2001; 17(5), S608-S612).
- the rms wavefront aberration increases significantly with the diameter of the pupil and can show large inter-subject variability.
- a small wavefront aberration value means better image quality on the retina and this translates to improved visual performance, (e.g., ability to see smaller or very faint objects, sharper and crisp images).
- FIG. 1 The reduction of higher-order wavefront aberrations in the human eye on administration of lutein and/or zeaxanthin can be seen from FIG. 1 .
- the number in parentheses is the number of subjects treated for 6 months with 20 mg/day zeaxanthin (Z), 20 mg/day lutein (L), 10 mg lutein+10 mg zeaxanthin per day (C, P—C), or placebo (P).
- composition denotes any composition that is suitable for administration to the human body, such as pharmaceutical preparations or dietary supplements in dosage unit form, or a food, or a beverage.
- a pharmaceutical preparation or dietary supplement in accordance with the present invention may be in any form that is conventional for oral administration, e.g. in solid form such as tablets including effervescent tablets, or soft or hard shell capsules, or in liquid form, such as solutions or suspensions, preferably oily suspension.
- these preparations may contain conventional carrier material, additives and adjuvants, which include water, gelatin, vegetable gums, sugars, vegetable oils, polyalkylene glycols, flavoring agents, preservatives, stabilizers, emulsifying agents, buffers and the like.
- the medicaments may be in the form of controlled (delayed) release formulations.
- the colorants as well as optional ingredients as defined earlier hereinabove may be incorporated in food or beverages, such as bakery items, e.g., cake and cookies, lemonades and fruit juices.
- the compositions according to the present invention may further contain physiologically active ingredients conventionally used to promote health, especially eye health, such as vitamins e.g. vitamin A, C and E, and minerals, such as selenium or zinc.
- a suitable daily dosage of lutein and/or zeaxanthin for the purposes of the present invention may be within the range from 0.001 mg per kg body weight to about 20 mg per kg body weight. More preferred is a daily dosage of about 0.01 to about 10 mg per kg body weight, and especially preferred is about 0.1 to 1.0 mg per kg body weight per day.
- the invention relates to the use of a combination of lutein and zeaxanthin.
- these compounds are preferably used in a ratio of 0.1-1.0:1.0-0.1 parts by weight.
- lutein and/or zeaxanthin are suitably present in an amount from about 0.1 mg to about 500 mg, preferably from about 1 mg to about 100 mg per dosage unit.
- the aforesaid ingredients are suitably present in an amount of from about 0.1 to about 5 percent by weight based upon the total weight of the composition.
- Preferred solid dosage unit preparations comprise, per dosage unit, about 6 mg to about 12 mg of lutein and/or zeaxanthin.
- a soft gelatin capsule may be prepared comprising the following ingredients: Ingredient Amount per Capsule Lutein 10 mg Lecithin 50 mg Soy bean oil 200 mg
- a soft gelatin capsule may be prepared comprising the following ingredients: Ingredient Amount per Capsule Lutein 10 mg Zeaxanthin 10 mg Lecithin 50 mg Soy bean oil 200 mg
- a soft gelatin capsule may be prepared comprising the following ingredients: Ingredient Amount per Capsule Lutein 6 mg Zeaxanthin 6 mg Vitamin E ( ⁇ -d,l-tocopherol) 200 mg Vitamin C 500 mg Lecithin 50 mg Soy bean oil 200 mg
- a soft gelatin capsule may be prepared comprising the following ingredients: Ingredient Amount per Capsule Lutein 12 mg Vitamin E ( ⁇ -d,l-tocopherol) 200 mg Vitamin C 500 mg Lecithin 50 mg Soy bean oil 200 mg
- a soft gelatin capsule may be prepared comprising the following ingredients: Ingredient Amount per Capsule Zeaxanthin 12 mg Vitamin E ( ⁇ -d,l-tocopherol) 200 mg Vitamin C 500 mg Lecithin 50 mg Soy bean oil 200 mg
- a soft gelatin capsule may be prepared comprising the following ingredients: Ingredient Amount per Capsule Lutein 6 mg Zeaxanthin 6 mg ⁇ -Carotene 6 mg Vitamin E ( ⁇ -d,l-tocopherol) 200 mg Vitamin C 500 mg Zinc (as orotate) 7.5 mg Lecithin 50 mg Soy bean oil 200
- a soft gelatin capsule may be prepared comprising the following ingredients: Ingredient Amount per Capsule Lutein 6 mg Zeaxanthin 6 mg Vitamin E ( ⁇ -d,l-tocopherol) 200 mg Vitamin C 500 mg Vitamin A 1000 Int. Units Zinc (as orotate) 7.5 mg Lecithin 50 mg Soy bean oil 200 mg
- a soft gelatin capsule may be prepared comprising the following ingredients: Ingredient Amount per Capsule Lutein 6 mg Zeaxanthin 6 mg ⁇ -Carotene 6 mg Vitamin E ( ⁇ -d,l-tocopherol) 200 mg Vitamin C 500 mg Vitamin A 1000 Int. Units Zinc (as orotate) 7.5 mg Lecithin 50 mg Soy bean oil 200 mg
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Eye Examination Apparatus (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Pharmaceutical compositions or dietary supplements are provided containing lutein, zeaxanthin, or mixtures thereof in amounts effective to improve image quality in the human eye. Methods are also provided for reducing higher order wavefront aberrations in the human eye to improve image quality by administering to a person in need of such treatment an effective amount of lutein, zeaxanthin or mixtures thereof.
Description
- The present invention relates to the improvement of image quality in the eye. The term “image quality” as used herein refers to the image formed on the retina. This image can be deteriorated by higher-order aberrations such as spherical aberrations, coma and irregular astigmatism.
- While lower-order aberrations limit how much we can see, higher-order aberrations determine how well we can see. Higher-order aberrations are aberrations of the optics of the eye above and beyond nearsightedness, farsightedness and astigmatism. Higher-order aberrations cannot be corrected easily with glasses or contact lenses. Higher-order wavefront aberrations describe small deviations of the wavefront surface from the ideal surface and the reproduction of these deviations require a large number of components. Two common and potentially disruptive higher order aberrations are “spherical aberration” and “coma” see Liang J, Williams D R; Aberrations and retinal image quality of the normal human eye; J. Opt. Soc. Am. A. 1997; 14 (11):2873-83). For the visual benefits of correcting higher-order aberrations of the eye see also Williams et al., Visual Benefit of Correcting Higher Order Aberrations of the Eye, J. Refract. Surg. 2001, 16 (September/October 2000) S554-S559.
- In accordance with the present invention it has been found that the administration of lutein and/or zeaxanthin leads to a reduction of higher-order wavefront aberrations in the eye. Thus, in one aspect, the invention relates to the use of lutein or zeaxanthin, or mixtures thereof, in the manufacture of a composition for reducing higher-order wavefront aberrations in the human eye. In another aspect, the present invention relates to a method of reducing higher-order wavefront aberrations in the human eye which comprises administering to a person in need of such treatment an effective amount of lutein or zeaxanthin, or mixtures thereof.
- The term “higher order wavefront aberrations in the eye” as used herein denotes aberrations of the optical system of the eye that are distinct from myopia, hyperopia and axial astigmatism but nevertheless influence the quality of the image formed on the retina. They are measured by commercially available apparatuses, and are expressed as the wavefront function, which completely describes the aggregate effects of all refractive parts of the eye on light passing through every location of the pupil.
- The wavefront aberration function is a way of quantifying the imperfections of the optics of the eye that cause degradation of retinal image quality. The “ideal” wavefront is generated when a “point” on the retina is imaged through the optics of the eye as a plane and flat surface just outside the eye. This means that all the rays emerging from the eye form a parallel bundle and are perpendicular to this plane. The “real” wavefront surface is not a perfect two-dimensional plane and reflects the aberrations present in the optical system. It is usually represented mathematically by a series of terms known as Zernike polynomials. A knowledge of the coefficients of the Zernike polynomials provides a complete description of the wavefront surface. In order to obtain one single number that describes the quality of the imaging system (in this case the human eye) the root mean square (rms) deviation is calculated by computing the root of the mean of the squares of the actual deviations from the ideal plane. The rms value is equivalent to a standard deviation, but the two functions compared are 2D surfaces (i.e., the ideal wavefront and the actual wavefront). The wavefront aberrations are measured with a wavefront analyzer (see, e.g., J. Refract. Surg. 2001; 17(5), S608-S612). The rms wavefront aberration increases significantly with the diameter of the pupil and can show large inter-subject variability. A small wavefront aberration value means better image quality on the retina and this translates to improved visual performance, (e.g., ability to see smaller or very faint objects, sharper and crisp images).
- The reduction of higher-order wavefront aberrations in the human eye on administration of lutein and/or zeaxanthin can be seen from
FIG. 1 . - In
FIG. 1 the number in parentheses is the number of subjects treated for 6 months with 20 mg/day zeaxanthin (Z), 20 mg/day lutein (L), 10 mg lutein+10 mg zeaxanthin per day (C, P—C), or placebo (P). - The term “composition” as used herein denotes any composition that is suitable for administration to the human body, such as pharmaceutical preparations or dietary supplements in dosage unit form, or a food, or a beverage.
- A pharmaceutical preparation or dietary supplement in accordance with the present invention may be in any form that is conventional for oral administration, e.g. in solid form such as tablets including effervescent tablets, or soft or hard shell capsules, or in liquid form, such as solutions or suspensions, preferably oily suspension. Besides the active ingredients these preparations may contain conventional carrier material, additives and adjuvants, which include water, gelatin, vegetable gums, sugars, vegetable oils, polyalkylene glycols, flavoring agents, preservatives, stabilizers, emulsifying agents, buffers and the like. The medicaments may be in the form of controlled (delayed) release formulations. For the purpose of the invention the colorants as well as optional ingredients as defined earlier hereinabove may be incorporated in food or beverages, such as bakery items, e.g., cake and cookies, lemonades and fruit juices. The compositions according to the present invention may further contain physiologically active ingredients conventionally used to promote health, especially eye health, such as vitamins e.g. vitamin A, C and E, and minerals, such as selenium or zinc.
- A suitable daily dosage of lutein and/or zeaxanthin for the purposes of the present invention may be within the range from 0.001 mg per kg body weight to about 20 mg per kg body weight. More preferred is a daily dosage of about 0.01 to about 10 mg per kg body weight, and especially preferred is about 0.1 to 1.0 mg per kg body weight per day.
- In a preferred aspect, the invention relates to the use of a combination of lutein and zeaxanthin. In such combination these compounds are preferably used in a ratio of 0.1-1.0:1.0-0.1 parts by weight.
- In solid dosage unit preparations, lutein and/or zeaxanthin are suitably present in an amount from about 0.1 mg to about 500 mg, preferably from about 1 mg to about 100 mg per dosage unit. In liquid formulations, the aforesaid ingredients are suitably present in an amount of from about 0.1 to about 5 percent by weight based upon the total weight of the composition.
- Preferred solid dosage unit preparations comprise, per dosage unit, about 6 mg to about 12 mg of lutein and/or zeaxanthin.
- The invention is illustrated further by the Examples given below:
- A soft gelatin capsule may be prepared comprising the following ingredients:
Ingredient Amount per Capsule Lutein 10 mg Lecithin 50 mg Soy bean oil 200 mg - A soft gelatin capsule may be prepared comprising the following ingredients:
Ingredient Amount per Capsule Lutein 10 mg Zeaxanthin 10 mg Lecithin 50 mg Soy bean oil 200 mg - A soft gelatin capsule may be prepared comprising the following ingredients:
Ingredient Amount per Capsule Lutein 6 mg Zeaxanthin 6 mg Vitamin E (α-d,l-tocopherol) 200 mg Vitamin C 500 mg Lecithin 50 mg Soy bean oil 200 mg - A soft gelatin capsule may be prepared comprising the following ingredients:
Ingredient Amount per Capsule Lutein 12 mg Vitamin E (α-d,l-tocopherol) 200 mg Vitamin C 500 mg Lecithin 50 mg Soy bean oil 200 mg - A soft gelatin capsule may be prepared comprising the following ingredients:
Ingredient Amount per Capsule Zeaxanthin 12 mg Vitamin E (α-d,l-tocopherol) 200 mg Vitamin C 500 mg Lecithin 50 mg Soy bean oil 200 mg - A soft gelatin capsule may be prepared comprising the following ingredients:
Ingredient Amount per Capsule Lutein 6 mg Zeaxanthin 6 mg β-Carotene 6 mg Vitamin E (α-d,l-tocopherol) 200 mg Vitamin C 500 mg Zinc (as orotate) 7.5 mg Lecithin 50 mg Soy bean oil 200 - A soft gelatin capsule may be prepared comprising the following ingredients:
Ingredient Amount per Capsule Lutein 6 mg Zeaxanthin 6 mg Vitamin E (α-d,l-tocopherol) 200 mg Vitamin C 500 mg Vitamin A 1000 Int. Units Zinc (as orotate) 7.5 mg Lecithin 50 mg Soy bean oil 200 mg - A soft gelatin capsule may be prepared comprising the following ingredients:
Ingredient Amount per Capsule Lutein 6 mg Zeaxanthin 6 mg β-Carotene 6 mg Vitamin E (α-d,l-tocopherol) 200 mg Vitamin C 500 mg Vitamin A 1000 Int. Units Zinc (as orotate) 7.5 mg Lecithin 50 mg Soy bean oil 200 mg
Claims (10)
1.-6. (canceled)
7. A method of reducing higher order wavefront aberrations in the human eye to improve image quality which comprises administering to a person in need of such treatment an effective amount of lutein or zeaxanthin, or mixtures thereof.
8. The method according to claim 7 wherein lutein is administered.
9. The method according to claim 7 wherein zeaxanthin is administered.
10. A method according to claim 7 wherein the daily dosage of lutein or zeaxanthin, or mixtures thereof is within the range of from 0.001 mg per kg body weight to about 20 mg per kg body weight, preferably from about 0.01 to about 10 mg per kg body weight, and most preferably from about 0.1 to 1.0 mg per kg body weight per day.
11. A pharmaceutical composition or dietary supplement in dosage unit form comprising an amount of lutein, zeaxanthin or mixtures thereof effective to improve image quality in a human eye.
12. A pharmaceutical composition or dietary supplement as in claim 11 , wherein the amount of lutein, zeaxanthin or mixtures thereof is effective to reduce higher order wavefront aberrations in the human eye.
13. A pharmaceutical composition or dietary supplement as in claim 11 , wherein the dosage unit form is for oral administration.
14. A pharmaceutical composition or dietary supplement as in claim 13 , wherein the dosage unit form comprises an amount of about 0.1 mg to about 500 mg of lutein, zeaxanthin or mixtures thereof.
15. A pharmaceutical composition or dietary supplement as in claim 13 , wherein the dosage unit form is a food or beverage.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04015189 | 2004-06-29 | ||
EP04015189.6 | 2004-06-29 | ||
PCT/EP2005/006168 WO2006002735A1 (en) | 2004-06-29 | 2005-06-08 | Improvement of image quality in the eye |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080045605A1 true US20080045605A1 (en) | 2008-02-21 |
Family
ID=35782481
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/629,997 Abandoned US20080045605A1 (en) | 2004-06-29 | 2005-06-08 | Image Quality in the Eye |
US13/064,404 Abandoned US20110172313A1 (en) | 2004-06-29 | 2011-03-23 | Image quality in the eye |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/064,404 Abandoned US20110172313A1 (en) | 2004-06-29 | 2011-03-23 | Image quality in the eye |
Country Status (9)
Country | Link |
---|---|
US (2) | US20080045605A1 (en) |
EP (1) | EP1761254B1 (en) |
JP (1) | JP5074184B2 (en) |
KR (1) | KR20070027649A (en) |
CN (1) | CN101094666B (en) |
AT (1) | ATE441406T1 (en) |
DE (1) | DE602005016405D1 (en) |
ES (1) | ES2331083T3 (en) |
WO (1) | WO2006002735A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080167384A1 (en) * | 2005-02-11 | 2008-07-10 | Wolfgang Schalch | Use of Zeaxanthin For the Treatment of Diseases of the Peripheral Retina |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT503329A1 (en) * | 2006-03-02 | 2007-09-15 | Omnica Gmbh | PROCESS FOR PREPARING A COMPOSITION CONTAINING AT LEAST ONE XANTOPHYLL |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5382714A (en) * | 1994-03-17 | 1995-01-17 | The Catholic University Of America | Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof |
US5827652A (en) * | 1995-10-31 | 1998-10-27 | Applied Food Biotechnology, Inc. | Zeaxanthin formulations for human ingestion |
US6075058A (en) * | 1998-12-12 | 2000-06-13 | Tufts University | Compositions for increased bioavailability of carotenoids |
US6110478A (en) * | 1996-06-12 | 2000-08-29 | Laboratoire Oenobiol | Composition having tanning and photoprotective activity, and its cosmetic applications |
US6218436B1 (en) * | 1993-06-28 | 2001-04-17 | The Howard Foundation | Pharmaceutically active carotenoids |
US20030081172A1 (en) * | 2001-10-25 | 2003-05-01 | Dreher Andreas W. | Eyeglass manufacturing method using variable index layer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997048388A1 (en) * | 1996-06-17 | 1997-12-24 | The Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
DE60318390T2 (en) * | 2002-01-30 | 2008-12-18 | Dsm Ip Assets B.V. | LUTEIN / ZEAXANTHIN AGAINST GLOSSY |
CN1481804A (en) * | 2002-12-17 | 2004-03-17 | 无锡杰西医药科技有限公司 | Eye nutrients formulation for prevention and cure of age-related cataract, macula lutea degradation and other eye disease , and its application method |
-
2005
- 2005-06-08 KR KR1020067027745A patent/KR20070027649A/en not_active Application Discontinuation
- 2005-06-08 JP JP2007519638A patent/JP5074184B2/en not_active Expired - Fee Related
- 2005-06-08 CN CN2005800202695A patent/CN101094666B/en not_active Expired - Fee Related
- 2005-06-08 EP EP05759460A patent/EP1761254B1/en not_active Not-in-force
- 2005-06-08 DE DE602005016405T patent/DE602005016405D1/en active Active
- 2005-06-08 ES ES05759460T patent/ES2331083T3/en active Active
- 2005-06-08 WO PCT/EP2005/006168 patent/WO2006002735A1/en active Application Filing
- 2005-06-08 AT AT05759460T patent/ATE441406T1/en not_active IP Right Cessation
- 2005-06-08 US US11/629,997 patent/US20080045605A1/en not_active Abandoned
-
2011
- 2011-03-23 US US13/064,404 patent/US20110172313A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218436B1 (en) * | 1993-06-28 | 2001-04-17 | The Howard Foundation | Pharmaceutically active carotenoids |
US5382714A (en) * | 1994-03-17 | 1995-01-17 | The Catholic University Of America | Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof |
US5827652A (en) * | 1995-10-31 | 1998-10-27 | Applied Food Biotechnology, Inc. | Zeaxanthin formulations for human ingestion |
US6110478A (en) * | 1996-06-12 | 2000-08-29 | Laboratoire Oenobiol | Composition having tanning and photoprotective activity, and its cosmetic applications |
US6075058A (en) * | 1998-12-12 | 2000-06-13 | Tufts University | Compositions for increased bioavailability of carotenoids |
US20030081172A1 (en) * | 2001-10-25 | 2003-05-01 | Dreher Andreas W. | Eyeglass manufacturing method using variable index layer |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080167384A1 (en) * | 2005-02-11 | 2008-07-10 | Wolfgang Schalch | Use of Zeaxanthin For the Treatment of Diseases of the Peripheral Retina |
Also Published As
Publication number | Publication date |
---|---|
KR20070027649A (en) | 2007-03-09 |
DE602005016405D1 (en) | 2009-10-15 |
EP1761254B1 (en) | 2009-09-02 |
ES2331083T3 (en) | 2009-12-21 |
JP5074184B2 (en) | 2012-11-14 |
JP2008505137A (en) | 2008-02-21 |
CN101094666A (en) | 2007-12-26 |
US20110172313A1 (en) | 2011-07-14 |
WO2006002735A1 (en) | 2006-01-12 |
EP1761254A1 (en) | 2007-03-14 |
CN101094666B (en) | 2010-09-29 |
ATE441406T1 (en) | 2009-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006176499A (en) | Therapeutic agent for eye disease | |
JP6998001B2 (en) | Food composition | |
EP4215190A1 (en) | Application of regulation of eye sclera lipid metabolism to inhibit myopia | |
US20130045940A1 (en) | Composition comprising as active ingredient l-carnitine in combination with a solar filter, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation | |
Kono et al. | Effect of multiple dietary supplement containing lutein, astaxanthin, cyanidin-3-glucoside, and DHA on accommodative ability | |
US20110172313A1 (en) | Image quality in the eye | |
JP5848042B2 (en) | Eye fatigue inhibiting composition and food and drink containing the same | |
US20080167384A1 (en) | Use of Zeaxanthin For the Treatment of Diseases of the Peripheral Retina | |
JP3778509B2 (en) | Agents for improving eye accommodation dysfunction | |
KR20230170963A (en) | Method and pharmaceutical composition for treating myopia | |
JP2020036561A (en) | Green tea composition for inhibition of reduction of cognitive function associated with workload | |
CN109222086A (en) | A kind of composition and its application and health food with efficacy of relieving visual fatigue | |
JP2020025503A (en) | Eye-aging preventive agent and eye-aging prevention supplement | |
AU2020352751B2 (en) | Composition of a dietary supplement and/or a nutritional additive for food, a unitary dosage form of said composition, and their use for improvement of the quality of visual performance including contrast sensitivity in persons in need of such an improvement, including persons suffering from at least one eye disease, particularly vitreous floaters | |
KR20110025824A (en) | Compounds useful for the prevention or treatment of accomodative asthenopia | |
RU2810755C2 (en) | Powder containing buffer salt and amino acid, dissolution of such powder to nutrient product and methods of use of such nutrient product | |
JP2006141410A (en) | Foods and drinks having effect of relieving eye controlling function errors | |
CN116999460A (en) | Nutrient formula for relieving visual fatigue and effect test method thereof | |
CN117243307A (en) | Composition with eye protection and eyesight improvement effects and application thereof in food or medicine preparation field | |
TW201914585A (en) | Composition for improving vision and intelligence and application thereof wherein the composition include DHA, algae oil, phospholipidylserine composition, mulberry extract and calendula extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DSM IP ASSETS B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BARBUR, JOHN;REEL/FRAME:018884/0411 Effective date: 20070120 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |